Clinical trial
Cyclophosphamide Followed by Intravenous Busulfan as Conditioning for Hematopoietic Cell Transplantation in Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome.
NCT00445744 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Cyclophosphamide Followed by Intravenous Busulfan as Conditioning for Hematopoietic Cell Transplantation in Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome.
- Lead sponsor
- Fred Hutchinson Cancer Center
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- December 31, 2006
- Completion date
- June 30, 2013
- Enrollment
- 52 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
adult acute myeloid leukemia in remission, adult acute myeloid leukemia with 11q23 (mll) abnormalities, adult acute myeloid leukemia with del(5q), adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with t(15;17)(q22;q12), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with t(8;21)(q22;q22), childhood acute myeloid leukemia in remission, childhood myelodysplastic syndromes, de novo myelodysplastic syndromes, essential thrombocythemia, myelodysplastic syndrome with isolated del(5q), polycythemia vera, previously treated myelodysplastic syndromes, primary myelofibrosis, recurrent adult acute myeloid leukemia, recurrent childhood acute myeloid leukemia, secondary acute myeloid leukemia, secondary myelodysplastic syndromes, secondary myelofibrosis, untreated adult acute myeloid leukemia, untreated childhood acute myeloid leukemia and other myeloid malignancies